BACKGROUND: Lymph node metastases are an important cause of treatment failure for pediatric and adolescent/young adult (AYA) sarcoma patients. Nodal sampling is recommended for certain sarcoma subtypes that have a predilection for lymphatic spread. Sentinel lymph node biopsy (SLNB) may improve the diagnostic yield of nodal sampling, particularly when single-photon emission computed tomography/computed tomography (SPECT-CT) is used to facilitate anatomic localization. Functional imaging with positron emission tomography/computed tomography (PET-CT) is increasingly used for sarcoma staging and is a less invasive alternative to SLNB. To assess the utility of these 2 staging methods, this study prospectively compared SLNB plus SPECT-CT with PET-CT for the identification of nodal metastases in pediatric and AYA patients. METHODS: Twenty-eight pediatric and AYA sarcoma patients underwent SLNB with SPECT-CT. The histological findings of the excised lymph nodes were then correlated with preoperative PET-CT imaging. RESULTS: A median of 2.4 sentinel nodes were sampled per patient. No wound infections or chronic lymphedema occurred. SLNB identified tumors in 7 of the 28 patients (25%), including 3 patients who had normal PET-CT imaging of the nodal basin. In contrast, PET-CT demonstrated hypermetabolic regional nodes in 14 patients, and this resulted in a positive predictive value of only 29%. The sensitivity and specificity of PET-CT for detecting histologically confirmed nodal metastases were only 57% and 52%, respectively. CONCLUSIONS: SLNB can safely guide the rational selection of nodes for biopsy in pediatric and AYA sarcoma patients and can identify therapy-changing nodal disease not appreciated with PET-CT. Cancer 2017;123:155-60.
INTRODUCTION
Metastatic involvement of regional lymph nodes is an important clinical problem for patients with soft tissue sarcoma. This finding most often occurs in patients with rhabdomyosarcoma, which constitutes nearly half of all soft tissue sarcomas seen in the pediatric and adolescent/young adult (AYA) population. 1 Regional nodal disease is identified in up to 23% of patients with extremity rhabdomyosarcoma 2 and is associated with worse outcomes. 2, 3 Although it is less common, nodal involvement can also be seen in clear cell sarcoma, epithelioid sarcoma, angiosarcoma, and occasionally synovial sarcoma. 4 The accurate detection of nodal metastases allows patients to receive appropriate additional therapy such as irradiation or completion lymphadenectomy, which can reduce subsequent recurrence rates. [5] [6] [7] Metastatic involvement is usually suspected when regional nodes are enlarged on examination or have an abnormal appearance on computed tomography (CT) or magnetic resonance imaging (MRI). However, both clinical and radiographic assessments may overestimate the presence of metastatic disease in the case of normal reactive nodes or underestimate tumor involvement if the node is not pathologically enlarged. For example, one cooperative group study reported that 17% of clinically normal lymph nodes were found to contain tumor at the time of biopsy, 8 and this underscores the need for effective nodal sampling in patients with a higher risk of regional spread so that potentially lifesaving therapies are not withheld.
Historically, random sampling of the anatomic regional lymph node basin has been performed, and this can lead to extensive dissection and morbidity such as infection, nerve damage, and lymphedema. Sentinel lymph node biopsy (SLNB) was designed as a rational alternative to random sampling with the hypothesis that the first (sentinel) node to receive lymphatic drainage from a tumor site would be most likely to contain metastatic tumor. SLNB is widely used for cancers such as melanoma and breast cancer, [9] [10] [11] and it has been used safely in pediatric melanoma and sarcoma. [12] [13] [14] [15] SLNB is performed via the injection of a technetium-99m-labeled colloid tracer and lymphazurin blue dye at the tumor site. Lymphoscintigraphy is then performed to identify the sentinel node or nodes noninvasively. The blue discoloration and a handheld c probe are then used to identify the sentinel node or nodes in the operative field.
Functional imaging using [
18 F]fludeoxyglucose positron emission tomography/computed tomography (FDG-PET-CT) is an attractive alternative to CT and MRI because it uses not just the size but also the metabolic characteristics of tissue to help to determine whether a metastatic tumor may be present. The sensitivity of this modality is based on the tumor cells' higher glycolytic rate and preferential retention of FDG versus normal cells, and it may allow the noninvasive detection of lymphatic metastasis. [16] [17] [18] [19] [20] Recent studies have suggested that PET-CT may be a sensitive and specific tool in the clinical determination of the extent of nodal disease in childhood sarcomas. [17] [18] [19] [20] [21] [22] [23] If nodal disease can reliably be identified with PET-CT, then it may be possible to omit the more invasive lymph node biopsies that are now routinely performed for these patients.
The purpose of this study was to prospectively compare the utility of SLNB plus single-photon emission computed tomography/computed tomography (SPECT-CT) with cross-sectional (MRI and CT) and functional imaging studies (PET-CT) for the identification of nodal metastases in pediatric and AYA sarcoma patients.
PATIENTS AND METHODS
Eligible patients included infants and children, adolescents, and young adults up to the age of 35 years treated for soft tissue sarcoma (eg, rhabdomyosarcoma, synovial clear cell sarcoma, epithelioid sarcoma, osteosarcoma, fibrosarcoma) at Cincinnati Children's Hospital Medical Center between 2009 and 2014. The study was approved by the local institutional review board. Written informed consent was obtained from the patient or the parent/ guardian, and assent was obtained from patients who were 11 years old or older before enrollment. Demographic, treatment-course, and pathologic diagnostic information were collected for all patients.
Evaluation of Lymph Node Disease
All patients underwent conventional CT or MRI and a PET-CT scan before SLNB. Regional nodes were considered suggestive of tumor on contrast-enhanced CT or MRI if they were pathologically enlarged (>1 cm on CT or MRI) or were < 1 cm on MRI with a loss of fatty hilum or they had greater FDG avidity than the background on PET-CT. All imaging studies were reviewed by 2 radiologists and the pediatric surgeon before SLNB was performed.
SLNB Technique
Indications for SLNB included the diagnosis of a sarcoma with a predilection for nodal spread and clinical concern about regional nodal disease in a sarcoma patient. The dosage of the technetium-99m sulfur colloid was filtered through a sterile 0.22-lm filter before use to remove the larger particles of the labeled sulfur colloid. Approximately 2 to 4 hours before the operative procedure, 125 mCi of the filtered technetium-99m sulfur microcolloid was injected intradermally in 4 quadrants around the tumor. Standard planar lymphoscintigraphy was then performed, and SPECT-CT was used to facilitate anatomic localization of the sentinel nodes (Fig. 1) . The images were again reviewed by 2 radiologists and the pediatric surgeon performing the SLNB before the patient was taken to the operating room. Intraoperatively, 3 mL of lymphazurin 1% dye (Isosulfan Blue, United States Surgical Corp, Norwalk, Conn) was injected into the dermal layer in 4 quadrants overlying the primary tumor site. A hand-held c probe was used to identify the area of maximal signal and thus guide dissection. Lymph nodes with radioactivity were removed until the remaining c count in the nodal basin was 10% of the first identified lymph node and was consistent with the background signal. In addition, any blue lymph nodes were removed. Either radioactive or blue nodes were considered sentinel nodes.
RESULTS
Twenty-eight pediatric and AYA soft tissue sarcoma patients, including 16 males and 12 females, were enrolled. Their ages ranged from 6 months to 32 years (median age, 16 6 10 y) and reflected the wide range of sarcoma patients seen at our tertiary referral center. The median follow-up after SLNB was 35 months (range, 11-Original Article 73 months), and 18 patients were alive and in remission at the last follow-up. At the time of this writing, 3 patients were alive with disease, and 7 had died. The primary tumor histology and location are further specified in Table  1 . None of these patients had clinical examination findings suspicious of nodal involvement, and none had extranodal metastases identified at diagnosis.
All patients had at least 1 sentinel node identified by a radioactive tracer or lymphazurin blue dye (median, 2.4; range, 1-7). In 26 of the 28 patients (93%), the c probe detected a radioactive signal; in 20 of the 28 patients (71%), the nodes were macroscopically dyed blue; and 19 of the 28 patients (68%) had both blue staining and a radioactive signal. The mean lymph node size, as (15, 30 , and 45 minutes after the injection of dye), which were then individually demonstrated with greater anatomic clarity via single-photon emission computed tomography/computed tomography. These nodes were proven histologically to contain tumor, despite their normal size. These images come from a patient with lower (Center) extremity sarcoma after tracer injection at the tumor site, which localized activity to 2 nonenlarged left inguinal lymph nodes and 1 nonenlarged external iliac node. All 3 nodes were found histologically to contain tumor.
determined by the pathologist, was 1.8 6 0.69 cm, and size was not predictive of malignancy.
Seven patients had tumors identified in sentinel nodes; they included 3 patients with alveolar rhabdomyosarcoma, 1 with embryonal rhabdomyosarcoma, 1 with clear cell sarcoma, 1 with epithelioid sarcoma, and 1 with angiomatoid fibrous histiocytoma. In 6 of these patients, the radiotherapy and/or chemotherapy plans were specifically adjusted because of the finding of nodal disease, as detailed in Table 2 . Four of the 7 patients were alive at the last follow-up.
Three of the 7 patients with proven malignant sentinel nodes (43%) had negative cross-sectional and functional imaging findings (PET specificity, 52%; CT specificity, 71%; MRI specificity, 64%), as shown in Table 3 . PET-CT suggested nodal involvement in many more patients than were actually found to harbor tumors, with increased FDG avidity seen in the regional nodal basin in 14 of the patients (50%). Because only 4 of those 14 patients were proven to have metastatic nodal spread, the positive predictive value of PET-CT to predict histologic evidence of nodal metastasis was 29%. The negative predictive value of PET-CT in this study was 79% (11/14) . Notably, the maximum standardized uptake value in nodal basins did not differ statistically between patients who had proven nodal involvement and those with suspected lymph node involvement (P 5 .9; data not shown).
The SLNB procedure was generally well tolerated, both acutely and with long-term observation (median follow-up, 35 months; range, 11-73 months). One patient developed transient lymphedema after SLNB was performed simultaneously with primary tumor resection, and there was full resolution within 4 months. Two patients developed superficial and mild paresthesia at the site of nodal biopsy. No patient had persistent lymphedema or wound infection.
DISCUSSION
Our study confirms previous reports of the feasibility and safety of performing SLNB in pediatric and AYA sarcoma patients. [13] [14] [15] [24] [25] [26] [27] Contemporary cooperative group protocols now require nodal sampling for patients with extremity rhabdomyosarcoma even without clinical or radiographic evidence of nodal metastasis because of the relatively high frequency of regional metastases and the possibility that physical examination and cross-sectional imaging may underestimate the presence of metastatic disease. The identification of nodal metastases is of critical importance because the accurate identification of nodal metastases can result in treatment modifications that may reduce the chance of subsequent recurrence. 28, 29 By targeting the most potentially relevant node or nodes with minimal morbidity, SLNB represents a rational approach to lymph node biopsy. SLNB can be also be performed at sites other than the extremities, specifically head/neck and trunk sites, where nodal drainage can often be very difficult to predict. 26 PET-CT has been recently reported to be an effective staging modality for rhabdomyosarcoma [16] [17] [18] [19] [20] [21] [22] [23] 30 : it can potentially identify more metastatic sites than can be appreciated with conventional cross-sectional imaging. In fact, PET-CT has been reported to have 94% sensitivity and 100% specificity for detecting nodal disease in pediatric patients with rhabdomyosarcoma. 30 However, these calculations involved only lymph nodes measuring more than 1 cm and used clinical follow-up alone for the majority of patients to determine whether nodes contained a tumor. In contrast, studies in which the utility of PET-CT was compared with SLNB showed functional imaging to have much lower sensitivity and specificity for detecting histologically proven nodal disease. For example, in highrisk melanoma, PET-CT has a reported sensitivity of only up to 40% when SLNB is used to confirm metastatic nodal disease. 31 In the only published pediatric study comparing PET-CT with SLNB in pediatric sarcoma patients, 3 of 8 patients had hypermetabolic regional nodes; this was consistent with metastases on PET-CT, but only 1 was found to contain tumor on SLNB. 15 In agreement with that smaller study, we have demonstrated that PET-CT had a positive predictive value of only 29%, and this suggests that PET-CT cannot be used exclusively for the identification of metastatic disease in the pediatric population and cannot be a substitute for tissue sampling. 13, 19, 25 This finding cannot be explained by minimal tumor burden alone in the histologically positive nodes because there was no correlation between disease burden per the pathology report and PET-CT detection. One of the metastatic sentinel nodes that was not detected on PET-CT had been replaced entirely by metastatic cells, whereas nodes with only small nests of microscopic disease were detected on PET-CT in 3 other patients. A likely cause of false-positives on PET may be the reactive changes following the initial biopsy of the primary tumor because SLNB is usually performed several days after the initial biopsy of the primary tumor site. In addition, nonspecific enlargement of lymph nodes in children is a common finding, even in the absence of malignant disease, and this may also contribute to the high false-positive rate on imaging. False-negatives may result from the relatively small size of some of the metastatic lymph nodes, particularly with minimal tumor burdens. Previous studies have suggested that PET-CT is less reliable for detecting tumor-containing lung metastases that are <0.8 cm, 20 and those lesions are presumably more homogeneous than some metastatic nodes containing admixtures of both tumor and normal nodal elements.
Our results confirm previous findings from smaller studies showing that PET-CT is not specific enough for nodal metastases such that biopsy can be avoided. Furthermore, even biopsies guided by examination, crosssectional imaging, or PET-CT may not correctly identify nodal metastases in patients, and this can potentially result in undertreatment. In contrast, SLNB can safely target the most clinically relevant nodes and potentially improve the diagnostic yield while reducing the need for and morbidity from excessive nodal sampling.
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